balinatunfib   Click here for help

GtoPdb Ligand ID: 13583

Synonyms: SAR-441566 | SAR441566
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: SAR441566 is a small molecule that binds to TNF and disrupts signalling [2]. The chemical structure is claimed in UCB Biopharma/Sanofi patent WO2016050975A1 [1] and is a match for the INN balinatunfib (from INN proposed list 131, Aug. 2024). Mechanistically, balinatunfib/SAR441566 stabilises the TNF trimer in an inactive conformation [2]. It has been proposed as an orally available alternative to deliver the same therapeutic outcome as anti-TNF biologics in chronic autoimmune diseases.

balinatunfib is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 95.88
Molecular weight 502.52
XLogP 0.95
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CN1[C@@H]2C[C@H](C3=C(C=CC=C3C1=O)OC(F)F)N4C5=C(C=CC(=C5)C6=CN=C(C7(CCC7)N)N=C6)N=C24
Isomeric SMILES CN1[C@@H]2C[C@H](C3=C(C1=O)C=CC=C3OC(F)F)N4C2=NC5=C4C=C(C=C5)C6=CN=C(N=C6)C7(CCC7)N
InChI InChI=1S/C27H24F2N6O2/c1-34-20-11-19(22-16(24(34)36)4-2-5-21(22)37-26(28)29)35-18-10-14(6-7-17(18)33-23(20)35)15-12-31-25(32-13-15)27(30)8-3-9-27/h2,4-7,10,12-13,19-20,26H,3,8-9,11,30H2,1H3/t19-,20-/m1/s1
InChI Key UROFXMLQPAUCGV-WOJBJXKFSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
SAR441566 was advanced to clinical evaluation in autoimmune diseases.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06073093 A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis Phase 2 Interventional Sanofi
NCT06073119 A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis Phase 2 Interventional Sanofi
NCT06637631 A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. Phase 2 Interventional Sanofi